Repare (RPTX) Q2 Loss Narrows 52%

Repare Therapeutics (NASDAQ:RPTX), a clinical-stage precision oncology company, released its second quarter 2025 earnings on August 8, 2025. The most notable news from the release was its GAAP net loss per share of $0.39, a much narrower loss than the consensus GAAP estimate of -$0.56. This outperformance was largely the result of a $5.7 million gain from the sale of its technology platforms, rather than recurring collaboration payments. In contrast, GAAP revenue was $0.3 million, substantially below the expected $5.0 million (GAAP) and also below the $1.1 million (GAAP) reported in the prior year. Expense reductions were a highlight, as research and development spend (GAAP) declined year-over-year and general and administrative costs dropped as well, confirming a shift toward a leaner, partnership-driven business model. Overall, the quarter featured aggressive cost control and progress on licensing deals, but little growth in underlying revenue. Source: Analyst estimates for the quarter provided by FactSet. Repare Therapeutics is a biotechnology company specializing in precision oncology. Its core strategy revolves around synthetic lethality, developing drugs that target cancer cells based on their unique genetic vulnerabilities. The company’s main technology platform, called SNIPRx, uses advanced gene-editing techniques to identify promising targets for cancer therapies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool